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HEALTH CARE DECISIONS USING OUTCOMES
RESEARCH CASE STUDY PRESENTATIONS
CASE STUDY PODIUM PRESENTATIONS
PODIUM SESSION I: CASE STUDIES I
CASE 1
REVIEWING THE REIMBURSEMENT STATUS OF
PHARMACEUTICALS—EXPERIENCES FROM SWEDEN
Engstrom A, Ramsberg J
Pharmaceutical Beneﬁts Board, Solna, Sweden
Organization: The Pharmaceutical Beneﬁts Board in Sweden
(LFN).
Problem or Issue Addressed: Uncertainty about the cost-
effectiveness of reimbursed products.
In Sweden, the Pharmaceutical Beneﬁts Board (LFN) was insti-
tuted in 2002 with the purpose of contributing to a rational and
cost-effective use of pharmaceuticals. The Board’s assignment is
to systematically and in accordance with national prioritization
guidelines decide which pharmaceuticals should be reimbursed.
Societal cost-effectiveness is a key decision parameter. One task
of the LFN is to review the subsidy status of all products (∼3000
products) that were already in the pharmaceutical beneﬁts when
the Board was instituted. Also these products should meet the
current requirements for cost-effectiveness.
Goals: These reviews serve two purposes. First and foremost, to
inform the Board’s decisions on subsidy status, second, to help
other decision makers in Swedish health care to use pharmaceu-
ticals rationally and cost-effectively. To meet both these objec-
tives, the reviews need to meet scientiﬁc standards and yet be
delivered in a timely fashion.
Outcomes Items used in the Decision: The scientiﬁc literature is
searched for systematic reviews and meta-analyses of effective-
ness and efﬁcacy data, evidence on the humanistic burden of
disease, as well as for health economic evaluations. If deemed
necessary, the LFN may perform additional health economic
analyses or modelling.
Implementation Strategy: The products have been classiﬁed into
49 groups (using three-digit ATC codes). A project team con-
sisting of a pharmacist/pharmacologist, a health economist and
a legal advisor is assembled for each review group. 3–4 external
clinical experts are also attached to the project group. These
experts are recruited based on nominations from stakeholders,
both from the health care system, patient groups and the phar-
maceutical industry. Companies marketing a product included in
a review are also asked to submit documentation about which
studies best support the effectiveness and cost-effectiveness of
their product. Before a report is published it is sent out for review
by the stakeholders involved.
Results: Two reviews have been completed so far (drugs against
migraine and acid related problems) and another six are cur-
rently in progress. The results from the review of drugs against
migraine resulted in one triptan being removed from reimburse-
ment and two manufacturers chose to lower their prices to make
their products cost-effective. Based on the review of drugs
against acid related problems the Board decided to remove two
proton pump inihibitors from reimbursement since they were
found not to be cost-effective compared to generic omeprazol.
H2-antagonists were removed from reimbursement based on
need and solidarity grounds. In addition to decisions to remove
individual products from reimbursement, recommendations on
cost-effective use of the pharmaceuticals were included in the
reports. The impact of such recommendations on clinical prac-
tice seems to be quite small according to the sales data.
Lessons Learned: Reviewing an entire group of pharmaceuticals
is time consuming especially in a small organization. It is
however possible to produce reports of a high quality which can
be used as a basis for decision making even with comparatively
limited resources by using existing systematic reviews and only
when necessary performing them within your own organization.
Substantial savings and better health outcomes are possible to
achieve if cost-effective strategies can be identiﬁed.
CASE 2
COST CONTROL FOR MENTAL HEALTH
Dubberly J1, Perri M2, Smith L1,Walthour A2
1The Georgia Department of Community Health, Atlanta, GA, USA,
2University of Georgia, Athens, GA, USA
Organization: The Georgia Department of Community Health
(DCH).
Problem or Issue Addressed: Rapidly rising costs of treating
mental illness in the Georgia Medicaid population
Goals: The Georgia Medicaid program has experienced rapidly
rising costs of treating mental illness. Along with this, clinical
studies have described the beneﬁts and risks of the various agents
used to treat mental illness. For this study, mental health drugs
included medications for: Attention Deﬁcit Hyperactive Disor-
der (ADHD), Selective Serotonin Reuptake Inhibitors (SSRI)
atypical antipsychotic agents and new generation antidepres-
sants. DCH sought to reduce the cost of treating mental illness
while maintaining quality of care provided to members. Cost
reduction was to be obtained by promoting the use of preferred
products in these categories through the traditional methods of
co-pay differentials (preferred and non-preferred agents), step
therapy protocols, as well as prior authorization.
Outcomes Items Used in the Decision Process: DCH utilized clin-
ical recommendations from the GA Drug Utilization Review
Board to deﬁne optimal therapy based on the clinical data. Clin-
ical input from practicing psychiatrists was also utilized to struc-
ture the program and exception criteria. Concerns raised by
national as well as local mental health advocacy organizations
also shaped the outcomes that were measured as part of this
effort. Costs were monitored by examining units of service, as
well as the total cost and numbers of prescriptions for central
nervous system medications for mental health patients. Hospital
admission rates, average length of hospital encounters, number
of emergency department visits, physician ofﬁce visits, as well as
loss of Medicaid eligibility due to incarceration were all included
in the outcome measures tracked.
Implementation Strategy: Prior to May 2004, all medications in
the therapeutic category were evaluated from a clinical perspec-
tive and recommendations made to DCH by the Drug Utiliza-
tion Review Board. Next, the net cost to the state, associated
with treatment with each agent was considered. Preferred and
Non preferred status was assigned to some agents, others were
included in step therapy protocols, and ﬁnally some agents were
only obtainable with prior authorization. Policy changes in drug
coverage were then phased in between May 1, 2004 and Novem-
ber 1, 2004 with all current users being grandfathered. The order
of implementation was ADHD, SSRI’s, Atypical Antipsychotic
agents and ﬁnally new generation antidepressants. Follow up to
monitor the outcomes measures (total payments, units of service,
the total cost and numbers of prescriptions for central nervous
system medications for mental health patients, hospital admis-
sion rates, average length of hospital encounters, emergency
department visits, physician ofﬁce visits, as well as loss of Med-
icaid eligibility due to incarceration) was conducted every three
months for two years following the policy changes.
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Results: The follow up monitoring of members receiving these
mental health drugs demonstrated a signiﬁcant savings in phar-
maceutical expenditures with no adverse effect of total health
care expenditures or utilization. The measures employed (i.e.
prior authorization, stepped therapy, and co-pay differentials)
did not appear to adversely affect persistence with these med-
ications. Additionally, disenrollment from Medicaid due to incar-
ceration did not increase among this group of members during
the observation period.
Lessons Learned: The inclusion of mental health drugs in a phar-
macy beneﬁt design is a controversial effort. Allowing continu-
ation of established therapy and requiring members new to
therapy with these mental health agents to go through a prudent,
clinically appropriate process to utilize the most cost-effective
medication available has the potential to decrease the cost of
pharmaceuticals without adversely affecting the utilization of
other more costly health care resources. When embarking on the
inclusion of mental health medications in a pharmacy design
beneﬁt that includes prior authorization and step therapy, it is
imperative that stakeholders have complete understanding of 
the reason for inclusion, the process to assure access to neces-
sary medications, as well as feedback regarding the outcomes
measured.
CASE 3
APPLICATION OF COST-EFFECTIVENESS ANALYSIS TO
EVALUATE THE PROPOSED FORMULARY STATUS OF A
NOVEL ANTIDIABETIC DRUG IN A U.S. COMMERCIAL
HEALTH PLAN
Watkins J1, Minshall M2, Sullivan SD3
1Premera Blue Cross, Mountlake Terrace, WA, USA, 2IMS-Health,
Noblesville, IN, USA, 3University of Washington, Pharmaceutical
Outcomes Research and Policy Program, Seattle, WA, USA
Organization: Premera Blue Cross Pharmacy and Therapeutics
Committee (P&T). Premera is a 1.6 million member regional
commercial health plan in the Paciﬁc Northwest of the U.S.
Problem or Issue Addressed: Need to determine formulary status
of Exenatide (Byetta), a recently marketed novel biologic agent
for the treatment of Type 2 Diabetes.
Goals: To test the usefulness of manufacturer-provided disease-
based cost-effectiveness models in helping formulary decision
makers to determine the value and appropriate place in therapy
for a new drug used to treat a chronic disease, when long-term
outcomes data for the new product are unavailable due to the
time required for long term sequelae of diabetes to be observed
in clinical trials.
Outcomes items used in the decision: Reduction in hemoglobin
A1c levels (A1c) and body mass index (BMI) observed in patients
receiving exenatide.
Implementation Strategy: Using the AMCP Format for Formu-
lary Submission (v2.1), Premera requested detailed information
from Amylin regarding the clinical and economic value of exe-
natide in a commercial health insurance population. Upon learn-
ing that Premera was requesting disease-based cost-effectiveness
modeling, Amylin purchased Web-based access to the CORE
Diabetes Model (CDM) for Premera staff. Amylin personnel
arranged training in the use of the model by CORE but no one
from Amylin participated in planning the modeling exercise,
choosing the input data and assumptions, or specifying the ana-
lytic scenarios. An informal Premera work group evaluated
various model scenarios and included a summary of the results
in the formulary recommendations to the P&T Committee.
Results: The model predicted reduced long-term treatment costs
in obese patients, driven by 11% decrease in cardiovascular
disease burden over a 30-year period. The incremental cost-effec-
tiveness ratio (ICER) for adding exenatide over 3 years was
$35,000/QALY. Using a 30-year horizon, ICER values were
$13,000/QALY versus insulin, $32,000 versus generic glyburide
and $16,000 versus no additional treatment. Exenatide domi-
nated pioglitazone. By comparison, the 30-year ICER for exe-
natide versus insulin in the non-obese cohort was $33,000. This
is a large longitudinal extrapolation based on relatively short
term trials, but it did help to conﬁrm the hypothesis that the drug
would beneﬁt a subgroup of obese patients. The P&T commit-
tee found this information useful and accepted staff recommen-
dation to add exenatide to formulary, with prior authorization
restrictions; however, due to limitations in the logistics of imple-
mentation, the restrictions did not limit use to obese patients.
Lessons Learned: Predicting long-term clinical outcomes of a
new drug from the results of short-term trials is challenging.
Good disease-based pharmacoeconomic models help payers
project costs, identify populations most likely to beneﬁt from
therapy, and perhaps craft restrictions that improve the poten-
tial for use of the drug in these populations, reducing the
numbers needed to treat and improving incremental cost-effec-
tiveness. In this context, a Format-compliant economic model
can facilitate communication between manufacturer and health
plan about the drug’s value.
PODIUM SESSION II: CASE STUDIES II
CASE 4
IMPLEMENTATION AND EVALUATION OF AN EVIDENCE-
BASED CONTINUUM FOR HIP AND KNEE REPLACEMENTS 
IN ALBERTA
Wasylak T1, Lahey M2, McBain D3, Frank C4, Gooch K5, Hibbert J5
1Calgary Health Region, Calgary, AB, Canada, 2Capital Health,
Edmonton, AB, Canada, 3David Thompson Health Region, Red Deer,
AB, Canada, 4University of Calgary, Calgary, AB, Canada, 5Institute of
Health Economics, Calgary, AB, Canada
Organization: Alberta Province [A new evidence-based contin-
uum (referral to recovery) for hip and knee replacements was
piloted in Alberta within the Calgary Health Region, the David
Thompson Health Region and Capital Health Region.]
Problem or Issue Addressed: Redesigning an evidence based con-
tinuum for hip and knee replacements.
Bone and joint related conditions place a heavy burden on health
care systems and can signiﬁcantly impact patient quality of life.
As the population ages and new technologies are emerging, there
is profound concern about the sustainability of care for patients
with bone and joint related conditions. The demand for hip and
knee replacements is increasing due to changes in patient demo-
graphics (e.g., obesity) and an aging population. This increasing
demand coupled with the current burden on health care
resources and increasingly long wait times emphasized the
urgency for health reform.
Goals: The three participating regional health authorities
(Capital Health, Calgary Health Region, David Thompson
Health Region) in conjunction with the Alberta Bone and Joint
Health Institute and other partners designed and tested a new
evidence based continuum of care for hip and knee replacements.
The goals of this new continuum included signiﬁcant improve-
ment in the areas of access, quality and cost. This newly designed
continuum coordinated the patient’s journey from referral to
recovery. Standardized clinical paths, patient education and
accountability, clinic care teams, and dedicated operating rooms
and inpatient units were examples of how the continuum was
redesigned. To evaluate the new continuum, a randomized con-
trolled evaluation was applied to ensure robust results that
